ImmunoGen Loses Trial Bid To Secure Cancer Therapy Patent
A Virginia federal judge issued a bench trial ruling Monday that ImmunoGen is not entitled to a patent on a cancer treatment, rejecting the company's claims for a second time after...To view the full article, register now.
Already a subscriber? Click here to view full article